Truist Securities Initiates Medincell's Coverage with a Buy Recommendation

Truist Securities initiated coverage on Medincell (MEDCL) with a Buy rating and a price target of €22, implying a 30% upside. The firm believes Medincell is well-positioned to capitalize on the growing long-acting injectable (LAI) market, citing the company's first approved product, UZEDY, and the anticipated FDA filing for Olanzapine LAI in H2 2025. Medincell's CEO views this coverage as an endorsement of the company's potential and a boost to its U.S. market expansion strategy.

Analysis

Truist Securities' initiation of coverage on Medincell (Paris:MEDCL) with a "Buy" rating and a €22 price target, implying a potential upside exceeding 30%, underscores the company's strategic positioning in the rapidly expanding long-acting injectable (LAI) market, which Truist estimates to be worth over €20 billion. The U.S. investment bank specifically cites Medincell's BEPO® technology as a key differentiator, enabling the development of next-generation drug delivery systems. This positive assessment is further substantiated by the robust U.S. market momentum of UZEDY®, Medincell's first FDA-approved LAI product for schizophrenia (commercialized by Teva), and the anticipated FDA submission for Olanzapine LAI, a significant antipsychotic, in the latter half of 2025. Medincell's CEO, Christophe Douat, interprets this coverage as a critical validation of the company's potential and a significant step in enhancing its visibility and strategic expansion within the U.S. biopharmaceutical sector.

Key Decisions for Investors

• Consider initiating or adding to positions in Medincell, given the strong "Buy" recommendation from Truist Securities, the substantial price target upside, and the company's leverage to the high-growth LAI market.
• Closely monitor key upcoming catalysts, including the sales trajectory of UZEDY® and the timely FDA filing and subsequent review process for Olanzapine LAI in H2 2025, as these will be critical determinants of near-term stock performance.
• Evaluate the increasing U.S. investor focus and potential for further positive re-ratings as Medincell executes on its U.S. expansion strategy and its LAI pipeline progresses.